248 related articles for article (PubMed ID: 16494633)
41. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients.
García de Olalla P; Martínez-González MA; Caylà JA; Jansà JM; Iglesias B; Guerrero R; Marco A; Gatell JM; Ocaña I;
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1051-7. PubMed ID: 12546112
[TBL] [Abstract][Full Text] [Related]
42. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
43. [Change in the survival of Cuban AIDS patients with tuberculosis in the Highly Active Antiretroviral Therapy (HAART) era].
Reyes-Corcho A; Capo de Paz V; Díaz-Jidy M; Pérez-Avila J; Bouza-Jiménez Y
Invest Clin; 2008 Sep; 49(3):309-20. PubMed ID: 18846772
[TBL] [Abstract][Full Text] [Related]
44. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
[TBL] [Abstract][Full Text] [Related]
45. Changes in mortality following HIV and AIDS and estimation of the number of people living with diagnosed HIV/AIDS in Australia, 1981-2003.
Nakhaee F; Black D; Wand H; McDonald A; Law M
Sex Health; 2009 Jun; 6(2):129-34. PubMed ID: 19457292
[TBL] [Abstract][Full Text] [Related]
46. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
47. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Gallafent JH; Buskin SE; De Turk PB; Aboulafia DM
J Clin Oncol; 2005 Feb; 23(6):1253-60. PubMed ID: 15718323
[TBL] [Abstract][Full Text] [Related]
48. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
[TBL] [Abstract][Full Text] [Related]
49. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.
Park WB; Choe PG; Kim SH; Jo JH; Bang JH; Kim HB; Kim NJ; Oh M; Choe KW
J Intern Med; 2007 Mar; 261(3):268-75. PubMed ID: 17305649
[TBL] [Abstract][Full Text] [Related]
50. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
Choi AI; Rodriguez RA; Bacchetti P; Volberding PA; Havlir D; Bertenthal D; Bostrom A; O'Hare AM
Clin Infect Dis; 2007 Dec; 45(12):1633-9. PubMed ID: 18190326
[TBL] [Abstract][Full Text] [Related]
51. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
[TBL] [Abstract][Full Text] [Related]
52. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
[TBL] [Abstract][Full Text] [Related]
53. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
54. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
[TBL] [Abstract][Full Text] [Related]
55. [Ocular manifestations in patients with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy].
Mesarić B; Lisić M; Kniewald T; Ugrinović N; Begovac J
Lijec Vjesn; 2005; 127(5-6):123-8. PubMed ID: 16281473
[TBL] [Abstract][Full Text] [Related]
56. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
[TBL] [Abstract][Full Text] [Related]
57. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART.
Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Gattinara GC; Esposito S; Viganò A; Giaquinto C; Rosso R; Guarino A; de Martino M
AIDS; 2007 Jul; 21(12):1607-15. PubMed ID: 17630556
[TBL] [Abstract][Full Text] [Related]
58. Optimizing the care of minority patients with HIV/AIDS.
Stone VE
Clin Infect Dis; 2004 Feb; 38(3):400-4. PubMed ID: 14727211
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients.
Lichterfeld M; Schmeisser N; Qurishi N; Vogel M; Brackmann HH; Spengler U; Rockstroh JK
J Infect; 2005 Apr; 50(3):221-8. PubMed ID: 15780416
[TBL] [Abstract][Full Text] [Related]
60. Study of patients diagnosed with advanced HIV in the HAART era--OMEGA Cohort.
Santos J; Palacios R; Ruiz J; González M; Márquez M
Int J STD AIDS; 2005 Mar; 16(3):252-5. PubMed ID: 15829028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
